Skip to content

MaxCyte MXCT Total debt

Total debt at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$987.3M-28.4%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$410.7M-5.5%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$1.04M-2.0%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$23.76M+301%
PDE
Pro-Dex, Inc.PDEX
$15.98M+43.2%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Calculated from MaxCyte’s reported figures.

Plus components not separately reported this period.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's total debt?
MaxCyte (MXCT) reported total debt of $17.49M in Q1 2026.
How has MaxCyte's total debt changed year-over-year?
MaxCyte's total debt decreased by 7.1% year-over-year, from $18.82M to $17.49M.
What is the long-term trend for MaxCyte's total debt?
Over 5 years (2020 to 2025), MaxCyte's total debt has grown at a 20.8% compound annual growth rate (CAGR), from $6.97M to $17.94M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.